Company Overview and News

27
Short seller who foresaw Valeant crash now bets on Tesla falling

2018-10-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
VRX LHHMQ MDXG BHS

 
Tesla’s value sinks by $10 billion in a week as rout deepens

2018-10-09 livemint
New York: If the rout sparked by an SEC investigation into CEO Elon Musk’s tweets on taking the carmaker private wasn’t enough, a subsequent tweet storm mocking the agency and an unflattering comparison to Lehman Brothers Holdings Inc. slewed off even more value. Shares extended losses for a fifth straight session Monday, falling 4.3% to the lowest in more than 18 months.
LHHMQ

 
Guardians of the global economy divided

2018-10-09 thestar.com.my
HONG KONG: A decade after the guardians of the world economy united to save it from depression, the scope for such shock-and-awe policies has all but dried up.
LHHMQ

 
Tesla's Value Sinks by $10 Billion in a Week as Rout Deepens

2018-10-08 theedgemarkets
If the rout sparked by an SEC investigation into CEO Elon Musk’s tweets on taking the carmaker private wasn’t enough, a subsequent tweet storm mocking the agency and an unflattering comparison to Lehman Brothers Holdings Inc. slewed off even more value. Shares extended losses for a fifth straight session Monday, falling 4.3 percent to the lowest in more than 18 months.
LHHMQ

1
'Despondent' Musk's Tesla resembles Lehman, Greenlight's Einhorn says

2018-10-05 reuters
NEW YORK (Reuters) - Hedge fund manager David Einhorn lambasted Tesla Inc (TSLA.O) and its “despondent” Chief Executive Elon Musk on Friday, comparing the electric car company to Lehman Brothers Holdings Inc, where he had flagged accounting problems several months before its 2008 collapse.
LHHMQ AAPL

 
Fed's Inflation Focus Needs A Tuneup

2018-10-02 seekingalpha
What now? Continued Federal Reserve interest-rate increases for as far as the eye can see? Those are the primary questions with the last inflation target standing essentially hitting the central bank's 2 percent bullseye.
LHHMQ

 
Sale of ”family silver” to bail out IL&FS

2018-09-30 freepressjournal.in
New Delhi: The Congress on Saturday came out heavily on the government using “family silver” of 38 crore Life Insurance Corporation (LIC) policy holders and small savings of the common people to bail out loss-making public sector banks and financial institutions.
500116 LHHMQ IDBI

 
'We don't consider political factors': Fed raises rates and says more are coming, brushing off Trump's concerns

2018-09-26 watoday.com.au
Federal Reserve officials raised interest rates for a third time this year and reaffirmed their outlook for further gradual hikes well into 2019, risking fresh criticism from President Donald Trump.
LHHMQ

 
US Federal Reserve raises rates, and says more coming

2018-09-26 financialexpress
Federal Reserve officials raised interest rates for a third time this year and reaffirmed their outlook for further gradual hikes well into 2019, risking fresh criticism from President Donald Trump.
LHHMQ

2
Could China find itself at the centre of the next financial crisis because of its mounting debt?

2018-09-26 scmp
China has been a force of stability in recent financial downturns, but may play a different role in future crises, analysts said.
LHHMQ AVF AIG 8685

 
'We don't consider political factors': Fed raises rates and says more are coming, brushing off Trump's concerns

2018-09-26 theage.com.au
Federal Reserve officials raised interest rates for a third time this year and reaffirmed their outlook for further gradual hikes well into 2019, risking fresh criticism from President Donald Trump.
LHHMQ

 
'We don't consider political factors': Fed raises rates and says more are coming, brushing off Trump's concerns

2018-09-26 smh.com.au
Federal Reserve officials raised interest rates for a third time this year and reaffirmed their outlook for further gradual hikes well into 2019, risking fresh criticism from President Donald Trump.
LHHMQ

 
US Federal Reserve increases interest rates, brushes off Donald Trump

2018-09-26 nzherald.co.nz
US Federal Reserve officials raised interest rates for a third time this year and reaffirmed their outlook for further gradual hikes well into 2019, risking fresh criticism from President Donald Trump.
LHHMQ

5
Lehman Brothers workers share memories 10 years after the fall

2018-09-21 reuters
NEW YORK (Reuters) - Ex-employees of Lehman Brothers Holdings Inc met at Irish pubs near their former office in Midtown Manhattan on Thursday night to reminisce 10 years after the bank’s collapse, in gatherings with the atmosphere of high school reunions despite marking the largest failure of the financial crisis.
JBK GSC TFG GSJ GS GLSSP LHHMQ GJS

5
Lehman Brothers workers share memories 10 years after the fall

2018-09-21 channelnewsasia
Ex-employees of Lehman Brothers Holdings Inc met at Irish pubs near their former office in Midtown Manhattan on Thursday night to reminisce 10 years after the bank's collapse, in gatherings with the atmosphere of high school reunions despite marking the largest failure of the financial crisis.
JBK GSC TFG GSJ GS GLSSP LHHMQ GJS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 524ESC100